Risk for GVHD compared with quartile of donor CD4+ and CD8+ T CD25 coexpression
. | Patients with acute GVHD (%) . | Hazard ratio vs quartiles 2-4 (95% CI) . | Patients with chronic GVHD (%) . | Hazard ratio vs quartiles 2-4 (95% CI) . |
|---|---|---|---|---|
| CD4+CD25+ T cells | ||||
| Quartile 1 | 1 of 15 (7) | 0.1 (0.01-0.9) | 2 of 15 (13) | 0.15 (0.02-1.2) |
| Quartile 2 | 6 of 15 (40) | — | 8 of 15 (53) | — |
| Quartile 3 | 8 of 15 (53) | — | 6 of 15 (40) | — |
| Quartile 4 | 7 of 15 (47) | — | 8 of 15 (53) | — |
| Quartiles 2-4 | 21 of 45 (47) | — | 22 of 45 (49) | — |
| CD8+CD25+ T cells | ||||
| Quartile 1 | 2 of 15 (13) | 0.2 (0.1-1.1) | 4 of 15 (27) | 0.3 (0.1-1.5) |
| Quartile 2 | 6 of 15 (40) | — | 4 of 15 (27) | — |
| Quartile 3 | 5 of 15 (33) | — | 9 of 15 (60) | — |
| Quartile 4 | 9 of 15 (60) | — | 7 of 15 (47) | — |
| Quartiles 2-4 | 20 of 45 (44) | — | 20 of 45 (44) | — |
. | Patients with acute GVHD (%) . | Hazard ratio vs quartiles 2-4 (95% CI) . | Patients with chronic GVHD (%) . | Hazard ratio vs quartiles 2-4 (95% CI) . |
|---|---|---|---|---|
| CD4+CD25+ T cells | ||||
| Quartile 1 | 1 of 15 (7) | 0.1 (0.01-0.9) | 2 of 15 (13) | 0.15 (0.02-1.2) |
| Quartile 2 | 6 of 15 (40) | — | 8 of 15 (53) | — |
| Quartile 3 | 8 of 15 (53) | — | 6 of 15 (40) | — |
| Quartile 4 | 7 of 15 (47) | — | 8 of 15 (53) | — |
| Quartiles 2-4 | 21 of 45 (47) | — | 22 of 45 (49) | — |
| CD8+CD25+ T cells | ||||
| Quartile 1 | 2 of 15 (13) | 0.2 (0.1-1.1) | 4 of 15 (27) | 0.3 (0.1-1.5) |
| Quartile 2 | 6 of 15 (40) | — | 4 of 15 (27) | — |
| Quartile 3 | 5 of 15 (33) | — | 9 of 15 (60) | — |
| Quartile 4 | 9 of 15 (60) | — | 7 of 15 (47) | — |
| Quartiles 2-4 | 20 of 45 (44) | — | 20 of 45 (44) | — |
—indicates not applicable.